Robust Pipeline with Large Market Potential
From our more advanced clinical program in Dupuytren’s disease to several preclinical programs ranging from an α7nAChR therapeutic for smoking cessation-induced ulcerative colitis to treatment of pain and early arthritis with SCAs, and several fibrosis and anti-TNF indications, our 3 families of drug candidates continue to meet milestones and show promising results.
We recently announced exciting results from our most advanced program in Dupuytren’s Contracture. The Phase 2b clinical trial was completed in 2021 and the published findings in The Lancet Rheumatology is available here.
Both the primary and secondary clinical trial endpoints from the Phase 2b clinical trial for patients with early-stage Dupuytren’s were statistically significant. Patients enrolled in the clinical trial exhibited a high compliance rate; almost all of them returned for all injections, and experienced no related serious adverse events.
In addition, a Phase 2 trial is projected to start in Q2/Q3 2023 in POCD.
Three families of novel drugs address significant market opportunities in inflammation, fibrosis and pain.
Pursuing Conditional Marketing Authorization in UK
Statistical significance was achieved in both the primary and secondary clinical trial endpoints.
Patients enrolled in the clinical trial exhibited a high rate of compliance; almost all returned for all injections.
No related serious adverse events.
Phase 2 Estimated start Q2/Q3 2023
Phase 2 results expected Q2 2025.
Feasibility Study closed for enrollment Q1 2023
New clinical site and country to be determined in 2023
Preclinical Started 2020
Preclinical started 2022